(Q37923861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

The CDK inhibitors in cancer research and therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Jonas Cicenas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Jonas Cicenas

series ordinal

1

1 reference

25 August 2017

30 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cancer Research and Clinical Oncology

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1409-1418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21877198%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00432-011-1039-4

11 February 2020

exact match

0 references

cites work

Phase II study of flavopiridol in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

An unusual member of the Cdk family: Cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Cyclin D3/CDK11(p58) complex involved in Schwann cells proliferation repression caused by lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase I study of flavopiridol and docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Secrets of a double agent: CDK7 in cell-cycle control and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

21 January 2018

Protein-tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Overexpression of CDK2 is a prognostic indicator of oral cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1039-4

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

12 December 2020

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

12 December 2020

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells

1 reference

12 December 2020

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

1 reference

12 December 2020

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

12 December 2020

Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients

1 reference

12 December 2020

The potential role of Akt phosphorylation in human cancers

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

12 December 2020

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells

1 reference

12 December 2020

Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features

1 reference

12 December 2020

Cyclin-dependent kinases: a family portrait.

1 reference

12 December 2020

Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis

1 reference

12 December 2020

Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression

1 reference

12 December 2020

Relationship between the RB1 mRNA level and the expression of phosphorylated RB protein in human breast cancers: their relevance in cell proliferation activity and patient clinical outcome

1 reference

12 December 2020

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

1 reference

12 December 2020

Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer

1 reference

12 December 2020

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

1 reference

12 December 2020

The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

1 reference

12 December 2020

Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen

1 reference

12 December 2020

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

1 reference

12 December 2020

Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor

1 reference

12 December 2020